MEI Pharma, Inc. (MEIP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MEI Pharma, Inc. (MEIP) trades at $3.07 with AI Score 37/100 (Grade D). MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing and commercializing cancer therapies. Market cap: $20.5M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 4, 2026Analyst Coverage for MEIP: MEIP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MEIP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MEIP: 3/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MEI Pharma, Inc. (MEIP) Healthcare & Pipeline Overview
MEI Pharma, Inc. is a late-stage biopharmaceutical company specializing in the development of cancer therapies, including Zandelisib for relapsed/refractory follicular lymphoma. The company operates through strategic collaborations and clinical trials to advance its pipeline of oncology drugs, addressing unmet needs in the healthcare sector.
What Is the Investment Thesis for MEIP?
MEI Pharma's investment thesis hinges on the successful development and commercialization of its lead drug candidate, Zandelisib, for relapsed/refractory follicular lymphoma. Positive Phase III trial results and subsequent regulatory approval could drive significant revenue growth. The company's collaborations with Kyowa Kirin and BeiGene provide additional validation and financial resources. Key value drivers include the expansion of Zandelisib into other B-cell malignancies and the advancement of Voruciclib, ME-344, and Pracinostat through clinical trials. A potential risk factor is the inherent uncertainty in drug development, including clinical trial failures and regulatory hurdles. With a market cap of $20.5M and a beta of 0.22, MEI Pharma presents a speculative investment opportunity within the biotechnology sector.
Based on FMP financials and quantitative analysis
MEIP Key Highlights
- Zandelisib is in Phase III clinical trial for relapsed/refractory follicular lymphoma, representing a potential near-term catalyst.
- Voruciclib is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies, expanding the pipeline's potential.
- ME-344 is in Phase I clinical trial for HER2-negative breast cancer, targeting a significant unmet need.
- Pracinostat is in Phase II clinical trial for myelodysplastic syndrome, offering another potential revenue stream.
- Strategic collaborations with Kyowa Kirin, BeiGene, and Helsinn Healthcare SA provide financial and operational support.
Who Are MEIP's Competitors?
MEIP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $129.78 | -2.57% | $161B | 94 |
| VRTX Vertex Pharmaceuticals Incorporated | $481.72 | +0.25% | $122B | 98 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | -9.09% | $7.95M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MEIP's Key Strengths?
- Late-stage drug candidates in clinical trials.
- Strategic collaborations with established pharmaceutical companies.
- Experienced management team.
- Diversified pipeline of oncology therapies.
What Are MEIP's Weaknesses?
- Limited financial resources.
- Dependence on clinical trial success.
- Competition from larger pharmaceutical companies.
- Regulatory risks.
What Could Drive MEIP Stock Higher?
- Zandelisib Phase III clinical trial results for relapsed/refractory follicular lymphoma.
- Voruciclib Phase Ib clinical trial results for acute myeloid leukemia and B-cell malignancies.
- Potential for new strategic partnerships and collaborations.
- Advancements in the clinical development of ME-344 and Pracinostat.
What Are the Key Risks for MEIP?
- Financial-distress signal — its Altman Z-Score of -1.39 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-90.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Zandelisib, Voruciclib, ME-344, or Pracinostat.
- Regulatory delays or rejections.
- Competition from other pharmaceutical companies developing cancer therapies.
- Dependence on funding and partnerships.
- Patent challenges or expirations.
What Are the Growth Opportunities for MEIP?
- Growth opportunity 1: Expanding Zandelisib's indications beyond relapsed/refractory follicular lymphoma represents a significant growth opportunity. The drug could potentially be used to treat other B-cell malignancies, such as diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL). This expansion strategy could be pursued within the next 2-3 years, pending clinical trial results and regulatory approvals.
- Growth opportunity 2: Advancing Voruciclib through clinical development for acute myeloid leukemia (AML) and other B-cell malignancies presents another key growth opportunity. AML is a particularly aggressive form of leukemia with a high unmet need for new therapies. Positive Phase Ib trial results could pave the way for Phase II and Phase III trials, potentially leading to regulatory approval and commercialization. The AML market is projected to grow significantly, driven by advances in targeted therapies. MEI Pharma could potentially launch Voruciclib within the next 3-5 years, contingent on clinical trial success.
- Growth opportunity 3: The development of ME-344 for HER2-negative breast cancer offers a targeted approach to treating this specific subtype of breast cancer. HER2-negative breast cancer accounts for a significant proportion of all breast cancer cases, representing a substantial market opportunity. MEI Pharma's mitochondrial inhibitor could potentially provide a novel treatment option for patients who have failed other therapies. The company aims to advance ME-344 through clinical trials and potentially seek regulatory approval within the next 4-6 years.
- Growth opportunity 4: Progressing Pracinostat through clinical trials for myelodysplastic syndrome (MDS) presents a strategic growth avenue. MDS is a group of blood disorders characterized by ineffective blood cell production. Pracinostat, as an oral histone deacetylase (HDAC) inhibitor, could potentially improve blood cell counts and reduce the need for transfusions in MDS patients. The MDS market is growing, driven by an aging population and advances in diagnostic techniques. MEI Pharma plans to continue clinical development of Pracinostat and potentially seek regulatory approval within the next 3-5 years.
- Growth opportunity 5: Strategic partnerships and collaborations represent a crucial growth opportunity for MEI Pharma. Collaborating with larger pharmaceutical companies and biotechnology firms can provide access to funding, expertise, and commercialization capabilities. MEI Pharma's existing partnerships with Kyowa Kirin, BeiGene, and Helsinn Healthcare SA demonstrate the value of this approach. The company could potentially seek additional partnerships to further advance its pipeline and expand its market reach. These collaborations can accelerate drug development timelines and increase the likelihood of commercial success. Ongoing:
What Opportunities Does MEIP Have?
- Expanding indications for existing drug candidates.
- Acquiring or licensing new drug candidates.
- Entering new geographic markets.
- Securing additional funding through partnerships or financing.
What Threats Does MEIP Face?
- Clinical trial failures.
- Regulatory setbacks.
- Competition from new therapies.
- Patent expirations.
What Are MEIP's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating the safety and efficacy of its therapies.
- Strategic partnerships with established pharmaceutical companies.
- Expertise in drug development and regulatory affairs.
What Does MEIP Do?
MEI Pharma, Inc., founded in 2000 and headquartered in San Diego, California, is a pharmaceutical company dedicated to the development and commercialization of novel cancer therapies. Originally named Marshall Edwards, Inc., the company rebranded as MEI Pharma in July 2012, signaling a renewed focus on oncology. The company's pipeline features a range of drug candidates targeting various types of cancer, including hematologic malignancies and solid tumors. Their lead drug candidate, Zandelisib, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, is currently in Phase III clinical trials for the treatment of patients with relapsed or refractory follicular lymphoma. Other key assets include Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, in Phase Ib clinical trials for acute myeloid leukemia and B-cell malignancies; ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex, in Phase I clinical trials for HER2-negative breast cancer; and Pracinostat, an oral histone deacetylase (HDAC) inhibitor, in Phase II clinical trials for myelodysplastic syndrome. MEI Pharma strategically collaborates with other companies to advance its programs, including Kyowa Kirin Company, BeiGene, Ltd., and Helsinn Healthcare SA. These partnerships provide financial support, clinical expertise, and commercialization capabilities.
What Products and Services Does MEIP Offer?
- Develops and commercializes therapies for the treatment of cancer.
- Focuses on hematologic malignancies and solid tumors.
- Develops Zandelisib, an oral PI3K delta inhibitor, for relapsed/refractory follicular lymphoma.
- Develops Voruciclib, an oral CDK9 inhibitor, for acute myeloid leukemia and B-cell malignancies.
- Develops ME-344, a mitochondrial inhibitor, for HER2-negative breast cancer.
- Develops Pracinostat, an oral HDAC inhibitor, for myelodysplastic syndrome.
- Engages in strategic collaborations with other pharmaceutical companies.
How Does MEIP Make Money?
- Develops and licenses pharmaceutical products.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partners with other companies for development, manufacturing, and commercialization.
- Generates revenue through licensing agreements and potential future product sales.
What Industry Does MEIP Operate In?
MEI Pharma operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and regulatory scrutiny. The market for cancer therapies is substantial and growing, driven by an aging population and increasing prevalence of cancer. MEI Pharma's focus on hematologic malignancies and solid tumors positions it within a high-growth segment of the pharmaceutical market. The company competes with larger pharmaceutical companies and other biotechnology firms developing similar therapies. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies.
Who Are MEIP's Key Customers?
- Patients with cancer, including follicular lymphoma, acute myeloid leukemia, breast cancer, and myelodysplastic syndrome.
- Healthcare providers who prescribe and administer cancer therapies.
- Pharmaceutical companies that partner with MEI Pharma for development and commercialization.
FY2026 estForward Outlook
Wall Street analysts project MEI Pharma, Inc. revenue of about $25.0M for fiscal 2026, with EPS near $-3.71.
ROE -91%Key Financial Metrics
Return on equity for MEI Pharma, Inc. stands at -90.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -32.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.53 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
MEI Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.39 places it in the distress zone, a signal of elevated financial risk.
MEIP Valuation & Market Position
With a $20.5M market cap, MEI Pharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, MEIP's quantitative score of 37/100 is below the peer average of 82/100.
MEIP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Late-stage drug candidates in clinical trials.
- Strategic collaborations with established pharmaceutical companies.
- Experienced management team.
- Diversified pipeline of oncology therapies.
Bear Case
- Limited financial resources.
- Dependence on clinical trial success.
- Competition from larger pharmaceutical companies.
- Regulatory risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MEIP Latest News
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Oct 21, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · May 17, 2022
MEIP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MEIP.
Price Targets
Wall Street price target analysis for MEIP.
MEIP MoonshotScore
What does this score mean?
The MoonshotScore rates MEIP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Justin J. File CPA
CEO
Justin J. File is the Chief Executive Officer of MEI Pharma, Inc. He is a Certified Public Accountant (CPA) with extensive experience in the pharmaceutical industry. Prior to joining MEI Pharma, File held various leadership positions in finance and operations at several biotechnology companies. His background includes expertise in financial management, strategic planning, and business development. File's experience in the healthcare sector spans over two decades, providing him with a deep understanding of the industry's challenges and opportunities.
Track Record: Since becoming CEO, Justin File has focused on advancing MEI Pharma's pipeline of oncology therapies through clinical trials and strategic partnerships. He has overseen the progression of Zandelisib into Phase III clinical trials and has secured collaborations with Kyowa Kirin and BeiGene. Under his leadership, MEI Pharma has strengthened its financial position and expanded its research and development efforts.
What Investors Ask About MEI Pharma, Inc. (MEIP) — Healthcare
What does the AI Score mean for MEIP?
MEIP holds an AI Score of 37/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing and commercializing cancer therapies. Their pipeline includes Zandelisib, Voruciclib, ME-344, and Pracinostat …
What does MEI Pharma, Inc. do?
MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing and commercializing novel cancer therapies. The company's pipeline includes Zandelisib, an oral PI3K delta inhibitor in Phase III clinical trials for relapsed/refractory follicular lymphoma; Voruciclib, an oral CDK9 inhibitor in Phase Ib trials for acute myeloid leukemia and B-cell malignancies; ME-344, a mitochondrial inhibitor in Phase I trials for HER2-negative breast cancer; and Pracinostat, an oral HDAC inhibitor in Phase II trials for myelodysplastic syndrome.
What do analysts say about MEIP stock?
Analyst coverage of MEIP stock is limited, reflecting the company's small market capitalization and speculative nature. Key valuation metrics are influenced by the potential success of Zandelisib and other pipeline assets. Growth considerations center on clinical trial outcomes, regulatory approvals, and commercialization strategies.
What are the main risks for MEIP?
The main risks for MEI Pharma include clinical trial failures, regulatory setbacks, competition from other pharmaceutical companies, dependence on funding and partnerships, and patent challenges or expirations. Clinical trial failures could significantly impact the company's valuation and future prospects. Regulatory delays or rejections could delay or prevent the commercialization of its drug candidates.
What are the key factors to evaluate for MEIP?
MEI Pharma, Inc. (MEIP) holds an AI score of 37/100 (low). Not financial advice.
How frequently does MEIP data refresh on this page?
MEIP's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MEIP's recent stock price performance?
MEI Pharma, Inc. (MEIP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Late-stage drug candidates in clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MEIP overvalued or undervalued right now?
MEI Pharma, Inc. (MEIP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MEIP before investing?
Before investing in MEI Pharma, Inc. (MEIP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment in biotechnology companies is inherently risky.